BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Express Scripts
Fish and Richardson
Johnson and Johnson
Boehringer Ingelheim
Moodys
Cerilliant
Deloitte
Covington
Healthtrust

Generated: January 20, 2018

DrugPatentWatch Database Preview

PARLODEL Drug Profile

« Back to Dashboard

When do Parlodel patents expire, and what generic alternatives are available?

Parlodel is a drug marketed by Us Pharms Holdings I and is included in one NDA.

The generic ingredient in PARLODEL is bromocriptine mesylate. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.
Drug patent expirations by year for PARLODEL
Pharmacology for PARLODEL
Ingredient-typeErgolines
Drug ClassErgot Derivative
Medical Subject Heading (MeSH) Categories for PARLODEL

US Patents and Regulatory Information for PARLODEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PARLODEL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Citi
McKinsey
Merck
Harvard Business School
Chubb
McKesson
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot